Yes, sir. What I did describe was the CARB-X project in my quick talk. The other is the GAIN legislation. It's called the GAIN Act. That provides longer intellectual property and different reimbursement incentives for antibiotics. That's something to think about. It's a little bit complex. That's really primarily it, the incentives. GAIN is an acronym, and I don't remember what the acronym stands for, but I will send it to you after this session so everybody knows what it is.
That's really what it is. It's longer intellectual property and it's slightly better reimbursement. Essentially it asks for the drugs not to be used or to be used extremely judiciously so that there is stewardship of the antibiotics.
As you may know, there hasn't been a new class of antibiotics. Dr. Wright can confirm this for me, but I think there hasn't been a new class of antibiotics since the 1980s. What we need are new classes of drugs to deal with the new microbes that are out there, or the evolving microbes that are out there. That's what these incentives are designed to do. We want to encourage drug makers and biotech firms to keep attempting to innovate.
I'm well aware that because of your health system, which I strongly support, there is a great need to limit reimbursement of medicines in Canada. It's something that may be somewhat in conflict with your system, but it is really something that you need to consider and you need to look at. You really do need to think about it. It's a balance you need to strike.